DCM
RAPP

DAFNA Capital Management’s Rapport Therapeutics RAPP Stock Holding History

DAFNA Capital Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.35M Hold
75,000
– – 0.53% 40
2025
Q4 		$2.28M Hold
75,000
– – 0.53% 45
2025
Q3 		$2.23M Buy
+75,000
New +$1.34M 0.55% 42

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

DAFNA Capital Management's RAPP Position: Q1 2026 in Review

DAFNA Capital Management held its Rapport Therapeutics (RAPP) position steady in Q1 2026 at 75,000 shares worth $2.35M. The position accounts for 0.53% of the portfolio, ranked #40.

DAFNA Capital Management first reported a position in RAPP in Q3 2025 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • DAFNA Capital Management held 75,000 shares of Rapport Therapeutics worth $2.35M as of Q1 2026.
  • DAFNA Capital Management left its Rapport Therapeutics share count unchanged in Q1 2026.
  • Rapport Therapeutics made up 0.53% of DAFNA Capital Management's portfolio in Q1 2026, its #40 holding.
  • DAFNA Capital Management first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.